First Tracks Biotherapeutics Announces Participation in Upcoming Investor Conferences

About this update from First Tracks Biotherapeutics, Inc.

SAN DIEGO, Calif., May 21, 2026 (GLOBE NEWSWIRE) -- First Tracks Biotherapeutics, Inc. (Nasdaq: TRAX), a clinical-stage biotechnology company advancing antibody therapeutics that modulate immune pathways implicated in autoimmune and inflammatory diseases, today announced that Daniel Faga, president and chief executive officer, and/or other members of its executive leadership team, are scheduled to participate in multiple upcoming investor conferences: 2026 Jefferies Global Healthcare Conference, New York Leerink Partners Therapeutics Forum, Boston A live webcast of the presentation will be available on the investor section of the First Tracks website at https://ir.firsttracksbio.com/news-events/events . A replay of the webcast will be available for at least 30 days following the event. About First Tracks Biotherapeutics First Tracks Biotherapeutics is a clinical stage biotechnology company advancing antibody therapies that modulate immune pathways implicated in autoimmune and inflammatory diseases. Its pipeline includes ANB033, a CD122 antagonist in development for celiac disease and eosinophilic esophagitis; rosnilimab, a pathogenic T cell depleter in development for rheumatoid arthritis; and ANB101, a BDCA2 modulator. To learn more, visit www.FirstTracksBio.com or follow us on LinkedIn . Investor Contact: Nick Montemarano Executive Director, Investor Relations 858.732.0178 [email protected]

View stock analysis, news, and events for First Tracks Biotherapeutics, Inc.